Table 1.

Patient demographics, responses and survival

						Doses administered		Responses		Survival
Pt No.	Age at Rx (years)	MYCN status	No. of prior relapses	Pre- study status	Pre-study MIBG score	131I-MIBG (actual) (MBq/kg)	AT (mg/kg/day)	INRC	Relative MIBG score	PFS (months)	OS (months)
Metastatic pheochromocytoma/paraganglioma
1	9.8	N/A	1	SD	7	656.6	0.15	N/A	1.00	63.1‡	63.1‡
2	13.3	N/A	1	SD	9	668.4	0.15	N/A	1.00	100.2‡	100.2‡
Neuroblastoma
3	9.2	NA	1	SD	13	444	0.15	NR	0.85	100.6‡	100.6‡
4	7.7	NA	0	SD	11	462.5	0.15	NR	1.00	79.2	99.0‡
5	9.9	NA	1	SD	8	673.2	0.15	NR	0.88	94.1‡	94.1‡
6	6.0	NA	2	PD	6	669.7	0*	NR	1.00	6.5	15.5
7	2.0	A	0	SD	2†	647.5	0.25	NR	1.00	91.8‡	91.8‡
8	2.8	NA	1	SD	20	677.1	0.25	NR	1.00	83.3‡	83.3‡
9	3.3	A	2	PD	2†	662.3	0.25	PD	1.00	0.9	3.7
10	4.7	NA	0	SD	14	632.7	0.25	NR	1.00	71.8‡	71.8‡
11	5.8	NA	5	PD	2†	662.3	0.25	PD	1.00	0.7	4.8
12	6.1	A	2	PD	21	691.9	0.25	PD	0.90	2.8	4.0
13	6.1	NA	4	PD	2†	677.1	0.25	PD	1.00	1.4	8.7
14	6.2	A	3	SD	5	662.3	0.25	PD	1.00	6.5	14.4
15	7.8	NA	4	SD	13	636.4	0.25	NR	1.00	3.7	14.7
16	8.3	NA	3	SD	21	658.6	0.25	NR	0.95	3.6	8.8
17	8.4	NA	0	SD	9	684.5	0.25	NR	0.88	83.3‡	83.3‡
18	8.4	NA	1	PD	10	654.9	0.25	PD	1.30	1.2	27.2
19	8.7	NA	3	PD	6	688.2	0.25	PD	1.50	1.2	9.8
20	15.2	NA	1	SD	9	647.5	0.25	NR	1.00	6.2	23.7
21	30.4	NA	2	PD	8	658.6	0.25§	NR	0.63	11.5	61.6

Abbreviations and Legend: A: Amplified; AT: Arsenic trioxide; INRC: International Neuroblastoma Response Criteria, N/A: not applicable; NA: Not amplified, No.: number, NR: No response; OS: overall survival; PFS: progression-free survival; PD: progressive disease; Pt: patient; Rx: treatment; SD: stable disease.

^*AT not administered due to central-line induced arrhythmia;

^†MIBG-avid soft tissue disease only;

^‡continue to be progression-free;

^§6/10 planned AT doses administered due to diarrhea and electrolyte imbalance